The role of chemotherapy for metastatic breast cancer

Hematology/Oncology Clinics of North America

Volumn 13, Issue 2, 1999, Pages 415-434

  Miller, K D ^a   Sledge Jr, G W ^a  

^a Indiana Cancer Pavilion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUOXYMESTERONE; GEMCITABINE; MITOXANTRONE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PREDNISONE; RAZOXANE; TAMOXIFEN; TAXANE DERIVATIVE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CYTOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; HORMONAL THERAPY; METASTASIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY;

EID: 0033031141     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70063-0     Document Type: Article

References (104)

1. American Society of Clinical Oncology Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer J Clin Oncol 14 1996 2843 2877
2. R. A'Hern I. Smith S. Ebbs Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens Br J Cancer 67 1993 801 805
3. O. Alabiso A. Durand A. Malossi Paclitaxel and epidoxorubicin regimen as first-line therapy in metastatic breast cancer. A phase I/II study Proceedings of the American Society of Clinical Oncology 17 1998 125
4. A. Alexopoulos C. Kouroussis S. Kakolyris A phase I/II study of docetaxel and mitoxantrone in metastatic breast cancer Proceedings of the American Society of Clinical Oncology 17 1998 128
5. K. Antman P. Rowlings W. Vaughan High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 15 1997 1870 1879
6. R. Asbury A. Chang L. Boros Weekly moderate-dose paclitaxel in advanced breast cancer Proceedings of the American Society of Clinical Oncology 17 1998 127
7. E. Baldini F. Innocenti A. Michelotti Paclitaxel by 3-hour infusion plus bolus epirubicin: A feasibility and pharmacokinetic study in metastatic breast cancer Ann Oncol 7 Suppl 5 1996 21
8. R. Basser Strategies for prevention of anthracycline cardiotoxicity Cancer Treat Rev 19 1993 57 77
9. L. Bastholt M. Dalmark S. Gjedde Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group J Clin Oncol 14 1996 1146 1155
10. W. Bezwoda R. Dansey L. Seymour First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine Oncology 46 1989 208 211
11. W. Bezwoda L. Seymour R. Dansey High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer. A randomized trial J Clin Oncol 13 1995 2483 2489
12. J. Bishop J. Dewar M. Tattersall Taxol (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic disease Proceedings of the American Society of Clinical Oncology 16 1997 153
13. M. Blackstein C. Vogel R. Ambinder Phase II study of gemcitabine in patients with metastatic breast cancer Proceedings of the American Society of Clinical Oncology 15 1996 117
14. H. Bloom Natural history of untreated breast cancer (1805–1933) BMJ 1 1962 213 221
15. J. Blum A. Buzdar P. LoRusso A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer Proceedings of the American Society of Clinical Oncology 107 1997 125
16. D. Budman N. Meropol B. Reigner Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine J Clin Oncol 16 1998 1795 1802
17. G. Capri E. Tarenzi A. Bertuzzi Paclitaxel by 3-hour infusion and bolus epirubicin on day 1 & 8 every three weeks in women with metastatic breast cancer Ann Oncol 7 Suppl 5 1996 16 22
18. J. Carmichael A. Jones T. Hutchinson A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee Semin Oncol 24 5 Suppl 17 1997 S17-44 S17-47
19. J. Carmichael K. Possinger P. Phillip Advanced breast cancer: A phase II trial with gemcitabine J Clin Oncol 13 1995 2731 2736
20. E. Cazap M. Ventriglia G. Rubio Taxol plus doxorubicin treatment of metastatic breast cancer in ambulatory patients Proceedings of the American Society of Clinical Oncology 15 1996 146
21. D. Chan R. Beveridge H. Muss Use of Truquant BR Radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease J Clin Oncol 15 1997 2322 2328
22. A. Coates V. Gebski M. Stat Improving quality of life during chemotherapy for advanced breast cancer N Eng J Med 317 1987 1490 1495
23. M. Cobleigh C. Vogel N. Tripathy Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer Proceedings of the American Society of Clinical Oncology 17 1998 97
24. R. Colomer A. Ruibal J. Genolla Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases Br Cancer Res Treat 13 1989 123 133
25. P. Conte A. Michelotti E. Baldini Epirubicin plus paclitaxel, a highly active combination devoid of significant cardiotoxicity in the treatment of metastatic breast cancer Proceedings of the American Society of Clinical Oncology 15 1996 118
26. R. Cooper Combination therapy in hormone resistant breast cancer Proceedings of the American Society for Cancer Research 10 1969 15
27. J. Cortes R. Pazdur Docetaxel J Clin Oncol 13 1995 2643 2655
28. J. Crown Summary of results of a randomized phase III trial of docetaxel versus doxorubicin in patients with metastatic breast cancer and prior alkylating agent exposure 20th Annual San Antonio Breast Cancer Conference 1997 Physicians' Education Resource San Antonio, TX 2 3
29. F. DiCostanzo A. Sdrobolini D. Bilancia Phase I–II trial of mitoxantrone and Taxol in advanced breast cancer Proceedings of the American Society of Clinical Oncology 15 1996 139
30. V. Dieras P. Fumoleau B. Chevallier Second EORTC Clinical Screening Group phase II trial of Taxotere (docetaxel) as first line chemotherapy in advanced breast cancer Proceedings of the American Society of Clinical Oncology 13 1994 78
31. A. Dixon L. Jackson S. Chan Continuous chemotherapy in responsive metastatic breast cancer: A role for tumour markers? Br J Cancer 68 1993 181 185
32. P. Dombernowsky M. Boesgaard E. Andersen Doxorubicin plus paclitaxel in advanced breast cancer Semin Oncol 24 4 Suppl 12 1997 S17-15 S17-18
33. J. Drebin V. Link M. Greene Monoclonal antibodies specific for the Neu oncogene product directly mediate anti-tumor effects in vivo Oncogene 2 1988 387 394
34. B. Ejlertsen P. Pfeiffer D. Pedersen Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months Eur J Cancer 29A 1993 527 531
35. E. Engelsman J. Klijn R. Rubens “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer Eur J Cancer 27 1991 966 970
36. G. Falkson R. Gelman K. Pandya Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment J Clin Oncol 16 1998 1669 1676
37. H. Falkson J. Van Der Watt M. Portugal Carcinoembryonic antigen in patients with breast cancer Cancer 42 1978 1308 1313
38. A. Fellous R. Ohayon T. Vacassin Biochemical effects of Navelbine on tubulin and associated proteins Semin Oncol 16 Suppl 4 1989 9 14
39. J. Fisherman K. Cowan M. Noone Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer J Clin Oncol 14 1996 774 782
40. G. Frassineti W. Zoli L. Silvestro Paclitaxel plus doxorubicin in breast cancer: An Italian experience Semin Oncol 24 5 Suppl 17 1997 S17-19 S17-25
41. P. Fumoleau B. Chevallier P. Kerbrat A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC Ann Oncol 7 1996 165 171
42. A. Gabizon Y. Barenholz M. Bialer Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs Pharm Res 10 1993 703 708
43. T. Gamucci M. Piccart P. Bruning Single agent Taxol versus doxorubicin as first-line chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with crossover Proceedings of the American Society of Clinical Oncology 17 1998 111
44. J. Gehl M. Boesgaard T. Paaske Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic Ann Oncol 7 1996 687 693
45. L. Gianni P. Dombernowsky G. Sledge Cardiac function following combination therapy with Taxol and doxorubicin for advanced breast cancer Proceedings of the American Society of Clinical Oncology 17 1998 115
46. L. Gianni E. Munzone G. Capri Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study J Clin Oncol 13 1995 2688 2699
47. F. Greco J. Hainsworth Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leukovorin in the treatment of metastatic breast cancer Semin Oncol 24 5 Suppl 17 1997 S17-61 S17-64
48. P. Greenberg G. Hortobagyi T. Smith Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 2197 2205
49. R. Gregory T. Powles J. Chang A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast Eur J Cancer 33 1997 2194 2197
50. A. Harris B. Cantwell J. Carmichael Comparison of short-term and continuous chemotherapy (mitoxantrone) for advanced breast cancer Lancet 1 1990 186 190
51. D. Hayes V.J. Zurawski D. Kufe Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer J Clin Oncol 4 1986 1542 1550
52. I. Henderson D. Hayes R. Gelman Dose-response in the treatment of breast cancer: A critical review J Clin Oncol 6 1988 1501 1515
53. F. Holmes V. Valero A. Buzdar Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer Proceedings of the American Society of Clinical Oncology 17 1998 110
54. F. Holmes R. Walters R. Theriault Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer J Natl Cancer Inst 83 1991 1797 1805
55. S. Honig Treatment of metastatic disease J. Harris M. Lippman M. Morrow Diseases of the Breast 1996 Lippincott-Raven Philadelphia 692 693
56. G. Hortobagyi G. Bodye A. Buzdar Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study J Clin Oncol 5 1987 354 364
57. W. Hrynuik H. Bush The importance of dose intensity in chemotherapy of metastatic breast cancer J Clin Oncol 2 1984 1281 1288
58. C. Hudis A. Seidman J. Crown Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 58 65
59. S. Jones E. Winer C. Vogel Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer J Clin Oncol 13 1995 2567 2574
60. P. Kerbrat P. Viens H. Roche Docetaxel in combination with epirubicin as 1st line chemotherapy of metastatic breast cancer: Final results Proceedings of the American Society of Clinical Oncology 17 1998 151
61. U. Kohler S. Olbricht G. Fuechsel Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: Results of a clinical phase II study Semin Oncol 24 5 Suppl 17 1997 S17-40 S17-43
62. S. Landis T. Murray S. Bolden Cancer statistics, 1998 CA Cancer J Clin 48 1998 6 29
63. R. Livingston G. Ellis J. Gralow Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer J Clin Oncol 15 1997 1395 1400
64. C. Loprinzi D. Tormey P. Rasmussen Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer J Clin Oncol 4 1986 46 56
65. H. Luck C. Thomssen A. du Bois Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer Semin Oncol 24 5 Suppl 17 1997 S17-35 S17-39
66. E. Mamounas A. Brown R. Smith Effect of Taxol duration of infusion in advanced breast cancer: Results from NSABP B-26 trial comparing 3- to 24-hr infusion of high dose Taxol Proceedings of the American Society of Clinical Oncology 17 1998 101
67. E. Mamounas C. Perex-Mesa R. Penetrante Patterns of occurrence of second primary nonmammary malignancies in breast cancer patients: Results from 1382 consecutive autopsies Surg Oncol 2 1993 175 185
68. M. Marin A. Lluch B. Ojeda Paclitaxel plus doxorubicin in metastatic breast cancer: Preliminary analysis of cardiotoxicity Semin Oncol 24 5 Suppl 17 1997 S17-26 S17-30
69. J. Misset V. Dieras L. Bozec Long term follow up of the phase I/II study of docetaxel and doxorubicin as 1st line chemotherapy of metastatic breast cancer Proceedings of the American Society of Clinical Oncology 17 1998 160
70. H. Muss L. Case F.I. Richard Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Peidmont Oncology Association N Eng J Med 325 1991 1342 1348
71. J.-M. Nabholtz Docetaxel, doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer 20th Annual San Antonio Breast Cancer Conference 1997 Physicians' Education Resource San Antonio, TX 7 9
72. J.-M. Nabholtz K. Gelmon M. Bontenbal Multicenter, randomized comparative trial of two doses of paclitaxel in patients with metastatic breast cancer J Clin Oncol 14 1996 1858 1867
73. D. Neuberg G. Sledge J. Fetting Changes in quality of life during induction therapy in patients enrolled in a randomized trial of Adriamycin, Taxol, and Adriamycin plus Taxol Proceedings of the American Society of Clinical Oncology 16 1997 54
74. J. O'Shaughnessy V. Moiseyenko D. Bell A randomized phase II study of Xeloda (capecitabine) vs. CMF as first line chemotherapy of breast cancer in women aged > 55 years Proceedings of the American Society of Clinical Oncology 17 1997 103
75. G. Panagos Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone Semin Oncol 24 1 Suppl 3 1997 S17-21
76. S. Parker T. Tong S. Bolden Cancer statistics, 1997 CA Cancer J Clin 47 1997 5 27
77. W. Peters R. Jones J. Vredenburgh A large, prospective, randomized trial of high-dose combination alkylating agents with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy Proceedings of the American Society of Clinical Oncology 15 1996 121
78. P. Pouna S. Bonoron-Adele G. Gouverneur Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: Comparison of new analogues versus doxorubicin Cancer Chemother Pharmacol 35 1995 257 261
79. Z. Rahman D. Frye A. Buzdar Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer J Clin Oncol 15 1997 3171 3177
80. M. Ranson J. Carmichael K. O'Byrne Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial J Clin Oncol 15 1997 3185 3191
81. P. Ravdin V. Valero H. Burris Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 1995 2879 2885
82. J. Robert Epirubicin: Clinical pharmacology and dose-effect relationship Drugs 45 Suppl 2 1993 20 30
83. E. Rowinsky R. Donehower Paclitaxel (Taxol) N Engl J Med 332 1995 1004 1014
84. D. Savarese H. Chung-cheng F. Stewart Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors J Clin Oncol 15 1997 2981 2995
85. G. Schwartsmann C. Menke M. Caleffi Phase II trial of Taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer Proceedings of the American Society of Clinical Oncology 15 1996 126
86. A. Seidman B. Murphy C. Hudis Activity of Taxol by weekly 1 hour infusion in patients with metastatic breast cancer: A phase II and pharmacologic study Proceedings of the American Society of Clinical Oncology 16 1997 148
87. D. Slamon W. Godolphin L. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
88. D. Slamon B. Leyland-Jones S. Shak Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial Proceedings of the American Society of Clinical Oncology 17 1998 98
89. G. Sledge D. Neuberg J. Ingle Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An Intergroup trial Proceedings of the American Society of Clinical Oncology 16 1997 1
90. G.J. Sledge Chemotherapy for metastatic breast cancer K. Bland E.J. Copeland The Breast 1998 WB Saunders and Co. Philadelphia 1324 1349
91. M. Stender D. Neuberg W. Wood Correlation of circulating c-erb B-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer Proceedings of the American Society of Clinical Oncology 16 1997 154
92. C. Stewart M. Ratain Topoisomerase interactive agents V. DeVita S. Hellmann S. Rosenberg Cancer. Principles and Practice of Oncology 1997 Lippincott-Raven Philadelphia 461 465
93. S. Swain F. Whaley M. Gerber Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 1997 1318 1332
94. S. Swain F. Whaley M. Gerber Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy J Clin Oncol 15 1997 1333 1340
95. I. Tannock N. Boyd F. Deboer A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for metastatic breast cancer J Clin Oncol 6 1988 1377 1387
96. M. Trudeau E. Eisenhauer B. Higgins Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada–Clinical Trials Group J Clin Oncol 14 1996 422 428
97. P. Valagussa G. Bonadonna U. Veronesi Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients Cancer 41 1978 1170 1178
98. P. Valagussa L. Gianni G. Capri Three-year follow-up in women with metastatic breast cancer after bolus doxorubicin and paclitaxel infused over 3 hours Proceedings of the American Society of Clinical Oncology 17 1998 111
99. V. Valero H. Burris S. Jones Multicenter pilot study of Taxotere in Taxol-resistant metastatic breast cancer Proceedings of the American Society of Clinical Oncology 15 1996 107
100. V. Valero A. Buzdar R. Walters Phase II study of TLC D-99 (liposomal doxorubicin), 5-FU, cyclophosphamide in patients with metastatic breast cancer Cancer Invest 13 Suppl 1 1995 29 30
101. V. Valero F. Holmes R. Walters Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J Clin Oncol 15 1995 141
102. M. Venturini A. Michelotti L. Del Mastro Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer J Clin Oncol 14 1996 3112 3120
103. B. Weber C. Vogel S. Jones Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer J Clin Oncol 13 1995 2722 2730
104. E. Winer D. Berry D. Duggan Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer Proceedings of the American Society of Clinical Oncology 17 1998 101